乙酰化依赖性USP7-TRIM25轴驱动非小细胞肺癌的癌性进展。

IF 9.6 1区 生物学 Q1 CELL BIOLOGY
Jian Yang, Zhike Chen, Wenxuan Hu, Weibiao Zeng, Zhe Lei, Xin Tong, Qifan Li, Gaomeng Luo, Kang Hu, Zhimeng Chen, Zeyi Liu, Chang Li, Chun Xu, Cheng Ding, Hong-Tao Zhang, Jun Zhao
{"title":"乙酰化依赖性USP7-TRIM25轴驱动非小细胞肺癌的癌性进展。","authors":"Jian Yang, Zhike Chen, Wenxuan Hu, Weibiao Zeng, Zhe Lei, Xin Tong, Qifan Li, Gaomeng Luo, Kang Hu, Zhimeng Chen, Zeyi Liu, Chang Li, Chun Xu, Cheng Ding, Hong-Tao Zhang, Jun Zhao","doi":"10.1038/s41419-025-08034-9","DOIUrl":null,"url":null,"abstract":"<p><p>Tripartite motif containing 25 (TRIM25), an E3 ubiquitin ligase that plays an important role in bioprocesses, is frequently elevated in malignant tumors. However, it remains unclear how TRIM25 protein expression is regulated in non-small cell lung cancer (NSCLC). Here, we find that TRIM25 is hyper-expressed in NSCLC tissues and associated with poor prognosis of NSCLC patients. Both in vitro and in vivo experiments indicate that TRIM25 facilitates tumor proliferation and metastasis. Mechanistically, acetylation is identified as a critical post-translational modification (PTM) regulating TRIM25 protein stability in NSCLC. The lysine acetyltransferase cAMP-responsive element-binding (CREB)-binding protein (CBP) mediates acetylation of TRIM25 at lysine 392, which is counteracted by the deacetylase Sirtuin 7 (SIRT7). Notably, the acetylation of TRIM25 enhances its interaction with ubiquitin specific peptidase 7 (USP7), resulting in reduced ubiquitination of TRIM25. In summary, our study reveals a novel acetylation modification site, thus providing new insights into an epigenetic regulation of TRIM25 in human cancer, and suggesting that pharmacological inhibition of TRIM25 acetylation is a potential anti-tumor strategy.</p>","PeriodicalId":9734,"journal":{"name":"Cell Death & Disease","volume":"16 1","pages":"695"},"PeriodicalIF":9.6000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501092/pdf/","citationCount":"0","resultStr":"{\"title\":\"Acetylation-dependent USP7-TRIM25 axis drives oncogenic progression in non-small cell lung cancer.\",\"authors\":\"Jian Yang, Zhike Chen, Wenxuan Hu, Weibiao Zeng, Zhe Lei, Xin Tong, Qifan Li, Gaomeng Luo, Kang Hu, Zhimeng Chen, Zeyi Liu, Chang Li, Chun Xu, Cheng Ding, Hong-Tao Zhang, Jun Zhao\",\"doi\":\"10.1038/s41419-025-08034-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tripartite motif containing 25 (TRIM25), an E3 ubiquitin ligase that plays an important role in bioprocesses, is frequently elevated in malignant tumors. However, it remains unclear how TRIM25 protein expression is regulated in non-small cell lung cancer (NSCLC). Here, we find that TRIM25 is hyper-expressed in NSCLC tissues and associated with poor prognosis of NSCLC patients. Both in vitro and in vivo experiments indicate that TRIM25 facilitates tumor proliferation and metastasis. Mechanistically, acetylation is identified as a critical post-translational modification (PTM) regulating TRIM25 protein stability in NSCLC. The lysine acetyltransferase cAMP-responsive element-binding (CREB)-binding protein (CBP) mediates acetylation of TRIM25 at lysine 392, which is counteracted by the deacetylase Sirtuin 7 (SIRT7). Notably, the acetylation of TRIM25 enhances its interaction with ubiquitin specific peptidase 7 (USP7), resulting in reduced ubiquitination of TRIM25. In summary, our study reveals a novel acetylation modification site, thus providing new insights into an epigenetic regulation of TRIM25 in human cancer, and suggesting that pharmacological inhibition of TRIM25 acetylation is a potential anti-tumor strategy.</p>\",\"PeriodicalId\":9734,\"journal\":{\"name\":\"Cell Death & Disease\",\"volume\":\"16 1\",\"pages\":\"695\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501092/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Death & Disease\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1038/s41419-025-08034-9\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Death & Disease","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1038/s41419-025-08034-9","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Tripartite motif containing 25 (TRIM25)是一种E3泛素连接酶,在生物过程中起重要作用,在恶性肿瘤中经常升高。然而,TRIM25蛋白在非小细胞肺癌(NSCLC)中的表达调控机制尚不清楚。本研究发现TRIM25在NSCLC组织中高表达,并与NSCLC患者预后不良相关。体外和体内实验均表明TRIM25促进肿瘤的增殖和转移。在机制上,乙酰化被认为是调节TRIM25蛋白稳定性的关键翻译后修饰(PTM)。赖氨酸乙酰转移酶cAMP-responsive element-binding (CREB)-binding protein (CBP)介导TRIM25在赖氨酸392位点的乙酰化,该乙酰化被去乙酰化酶Sirtuin 7 (SIRT7)抵消。值得注意的是,TRIM25的乙酰化增强了它与泛素特异性肽酶7 (USP7)的相互作用,导致TRIM25的泛素化降低。总之,我们的研究揭示了一个新的乙酰化修饰位点,从而为TRIM25在人类癌症中的表观遗传调控提供了新的见解,并提示药物抑制TRIM25乙酰化是一种潜在的抗肿瘤策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Acetylation-dependent USP7-TRIM25 axis drives oncogenic progression in non-small cell lung cancer.

Tripartite motif containing 25 (TRIM25), an E3 ubiquitin ligase that plays an important role in bioprocesses, is frequently elevated in malignant tumors. However, it remains unclear how TRIM25 protein expression is regulated in non-small cell lung cancer (NSCLC). Here, we find that TRIM25 is hyper-expressed in NSCLC tissues and associated with poor prognosis of NSCLC patients. Both in vitro and in vivo experiments indicate that TRIM25 facilitates tumor proliferation and metastasis. Mechanistically, acetylation is identified as a critical post-translational modification (PTM) regulating TRIM25 protein stability in NSCLC. The lysine acetyltransferase cAMP-responsive element-binding (CREB)-binding protein (CBP) mediates acetylation of TRIM25 at lysine 392, which is counteracted by the deacetylase Sirtuin 7 (SIRT7). Notably, the acetylation of TRIM25 enhances its interaction with ubiquitin specific peptidase 7 (USP7), resulting in reduced ubiquitination of TRIM25. In summary, our study reveals a novel acetylation modification site, thus providing new insights into an epigenetic regulation of TRIM25 in human cancer, and suggesting that pharmacological inhibition of TRIM25 acetylation is a potential anti-tumor strategy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cell Death & Disease
Cell Death & Disease CELL BIOLOGY-
CiteScore
15.10
自引率
2.20%
发文量
935
审稿时长
2 months
期刊介绍: Brought to readers by the editorial team of Cell Death & Differentiation, Cell Death & Disease is an online peer-reviewed journal specializing in translational cell death research. It covers a wide range of topics in experimental and internal medicine, including cancer, immunity, neuroscience, and now cancer metabolism. Cell Death & Disease seeks to encompass the breadth of translational implications of cell death, and topics of particular concentration will include, but are not limited to, the following: Experimental medicine Cancer Immunity Internal medicine Neuroscience Cancer metabolism
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信